From the Food and Drug Administration.
Nightingale
S L
SL
D000230:Adenocarcinoma / Q000188:drug therapy; D000578:Amidines / Q000627:therapeutic use*; D000740:Anemia / Q000188:drug therapy*; D000962:Antimalarials / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy*; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007978:Levamisole / Q000627:therapeutic use*; D008288:Malaria / Q000188:drug therapy* / Q000517:prevention & control; D015767:Mefloquine; D010419:Pentamidine / Q000008:administration & dosage / Q000627:therapeutic use*; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control*; D011804:Quinolines / Q000627:therapeutic use*; D011994:Recombinant Proteins
D000578:Amidines; D000962:Antimalarials; D011804:Quinolines; D011994:Recombinant Proteins; D004921:Erythropoietin; D007978:Levamisole; D010419:Pentamidine; D015767:Mefloquine